30 completed, 13 terminated, 3 unknown, 2 withdrawn. 22 Phase 1, 15 Phase 2, 8 Phase 3, 7 Phase 4, 1 Early Phase 1.
Follow lorcaserin: new trials by email Literature Review of lorcaserin trials Research Report on lorcaserin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lorcaserin in Treating Chemotherapy-Induced Peripheral Neuropathy in Patients With Stage I-IV Gastrointestinal or Breast Cancer Lorcaserin, Lorcaserin Hydrochloride, Questionnaire Administration - Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8 | Phase 1 | Withdrawn | Ohio State University Comprehensive Cancer Center | 2020-11-01 | 2021-01-19 | |
| A Study of Lorcaserin as Adjunctive Treatment in Participants With Dravet Syndrome Placebo, Lorcaserin - Epilepsies, Myoclonic | Phase 3 | Terminated | Eisai Inc. | 22 | 2020-09-23 | 2025-10-08 |
| Mechanisms of Lorcaserin for Smoking Cessation Lorcaserin Oral Tablet, Placebo oral tablet - Tobacco Use Disorder, Smoking Cessation | Phase 2 | Terminated | The Mind Research Network | 3 | 2019-12-04 | 2023-03-20 |
| Laboratory Screening of Lorcaserin for Alcohol Use Disorder Lorcaserin Oral Tablet, Placebo oral tablet - Alcohol Use Disorder, Tobacco Smoking | Phase 2 | Terminated | The Mind Research Network | 5 | 2019-10-25 | 2022-09-07 |
| Lorcaserin and Behavioral Modification for Overweight and Obesity Management in Chinese Obese Patients Lorcaserin 10 mg BID, Matching Placebo BID - Obesity | Phase 3 | Terminated | Kanion & Huawe Medicine Co.,Ltd | 100 | 2019-09-17 | 2022-05-02 |
| Lorcaserin for Cannabis Use Disorder Lorcaserin, Placebo oral capsule - Cannabis Use Disorder | Early Phase 1 | Terminated | New York State Psychiatric Institute | 5 | 2019-08-01 | 2021-01-28 |
| Comparing Lorcaserin Versus Duloxetine for the Treatment of Chemotherapy-Induced Peripheral Neuropathy Duloxetine 60 mg qd, Lorcaserin - Chemotherapy-Induced Peripheral Neuropathy | Phase 2 | Unknown | Southeastern Regional Medical Center | 50 | 2019-06-01 | 2019-04-04 |
| Rebalancing the Serotonergic System in Cocaine Dependence Lorcaserin, Placebo Oral Tablet - Cocaine Dependence | Phase 1 | Withdrawn | Mclean Hospital | 2018-10-04 | 2025-10-20 | |
| A Study to Demonstrate Bioequivalence Between Lorcaserin Extended Release (XR) Tablets Manufactured in Kawashima and Lorcaserin XR Tablets Manufactured in Zofingen in Healthy Participants Lorcaserin manufactured at Zofingen, Lorcaserin manufactured at Kawashima - Healthy Participants | Phase 1 | Completed | Eisai Inc. | 40 | 2018-08-07 | 2018-10-17 |
| Gene-by-Stress Interactions in Intervention Studies Significance Ziprasidone, Lorcaserin, Placebo Oral Tablet - Cardiovascular Diseases | Phase 1 | Terminated | Duke University | 7 | 2018-05-24 | 2020-02-17 |
| Predictors of Lorcaserin-Induced Weight Loss Belviq, Placebo - Overweight and Obesity | Phase 4 | Terminated | Columbia University | 32 | 2018-01-03 | 2024-03-27 |
| Treatment With Lorcaserin for Cocaine Use: The TLC Study lorcaserin, Placebo Oral Tablet, Substance use counseling - Cocaine Use Disorder | Phase 2 | Terminated | Glenn-Milo Santos | 22 | 2018-01-01 | 2023-08-14 |
| Lorcaserin in the Treatment of Cocaine Use Disorder Lorcaserin, Placebo Oral Capsule - Cocaine-Related Disorders | Phase 2 | Completed | National Institute on Drug Abuse (NIDA) | 272 | 2017-12-19 | 2020-08-05 |
| Study to Evaluate the Efficacy and Safety of Belviq XR® in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 Years lorcaserin hydrochloride XR, Placebo - Obesity | Phase 4 | Terminated | Eisai Inc. | 278 | 2017-09-28 | 2021-07-19 |
| Effect of Lorcaserin on Cannabis Withdrawal and Self-administration Lorcaserin, Placebo, Marijuana - Cannabis Use | Phase 1 / Phase 2 | Completed | New York State Psychiatric Institute | 15 | 2017-09-05 | 2022-07-26 |
| Lorcaserin in Combination With XR-Naltrexone for Relapse Prevention in Opioid Use Disorder Lorcaserin, Placebo - Opioid-use Disorder | Phase 2 / Phase 3 | Completed | New York State Psychiatric Institute | 60 | 2017-05-25 | 2020-10-05 |
| Lorcaserin: Real World Experience in an Insurance-Based Weight Management Clinic Lorcaserin - Obesity, Weight Loss | Completed | Scripps Whittier Diabetes Institute | 157 | 2017-04-11 | 2019-10-31 | |
| Drug Interaction and Subjective Effects of Compounds for Opioid Use Disorder Lorcaserin, Placebo - Opioid Abuse, Opioid Dependence | Phase 1 | Completed | Virginia Commonwealth University | 32 | 2017-01-30 | 2020-11-12 |
| Combination Nicotine Patch / Lorcaserin for Smoking Cessation lorcaserin, nicotine patch, placebo lorcaserin - Nicotine Dependence | Phase 2 | Completed | Duke University | 97 | 2016-11-08 | 2019-05-07 |
| Use of a Mobile Health Sensor in an Open Label Trial of Lorcaserin for the Treatment of Cannabis Use Disorder lorcaserin, Fitbit Charge HR - Cannabis Use Disorder | Phase 1 | Completed | New York State Psychiatric Institute | 17 | 2016-10-01 | 2019-10-11 |
Showing 20 of 50. Sign in to see all of them.
Obesity (21) · Weight Loss (10) · Overweight (9) · Cardiovascular Diseases (5) · Cocaine-Related Disorders (4) · Smoking Cessation (4) · Dyslipidemias (3) · Hypertension (3) · Opioid-Related Disorders (3) · Sleep Apnea Syndromes (3) · Tobacco Use Disorder (3) · Anorexia (2) · Epilepsies, Myoclonic (2) · Weight Gain (2) · Alcoholism (1)
Eisai Inc. (18) · New York State Psychiatric Institute (4) · Mayo Clinic (3) · Virginia Commonwealth University (3) · Duke University (2) · National Institute on Drug Abuse (NIDA) (2) · The Mind Research Network (2) · Arena Pharmaceuticals (1) · Beth Israel Deaconess Medical Center (1) · Columbia University (1) · Eisai Co., Ltd. (1) · Glenn-Milo Santos (1) · IlDong Pharmaceutical Co Ltd (1) · Johns Hopkins University (1) · Kanion & Huawe Medicine Co.,Ltd (1)
United States (46) · Canada (3) · Australia (1) · Chile (1) · China (1) · Japan (1) · Mexico (1) · New Zealand (1) · Poland (1) · South Korea (1) · The Bahamas (1)
Christian Hendershot, Ph.D. (2) · Eric Claus, Ph.D. (2) · Frederick G Moeller, MD (2) · Amy Janes, PhD (1) · Christina Brezing, MD (1) · Christos S Mantzoros, MD DSc (1) · Dale M Needham, MD, PhD (1) · Debra Kelsh, Ph.D. (1) · Donald Anderson, M.D. (1) · Frances R Levin, MD (1) · Glenn-Milo Santos, PhD, MPH (1) · Ivana T. Croghan, PhD (1) · James Bjork, PhD (1) · Jed E. Rose, Ph.D. (1) · Ken Fujioka, MD (1)
PMID 23661689, PMID 27206567, PMID 27659698, PMID 27888609, PMID 28365033, PMID 27116910, PMID 34611902, PMID 19057523, PMID 20647200, PMID 21190985, PMID 21795446, PMID 22421927, PMID 24500151, PMID 27385157, PMID 27389084, PMID 27708788, PMID 27815511, PMID 27852796, PMID 28124502, PMID 28345809, PMID 28440045, PMID 28600158, PMID 29288545, PMID 29363287, PMID 29676530, PMID 29803985, PMID 30145941, PMID 30191502, PMID 30293771, PMID 30304382, PMID 30586726, PMID 30811963, PMID 31589323, PMID 34265007, PMID 36160639, PMID 36897161, PMID 39021751
U54DA038999 (3), K23DA037299 (1), P01HL036587 (1), P30CA016058 (1), P50DA027840 (1), R01DK093920 (1), R01DK105526 (1), R34DA042161 (1), UL1TR001079 (1)